Riociguat-13C-d3

Confirm delete?

Riociguat-¹³C-d₃

Zoom

Cat No: 25314

Biochemicals - Isotopically Labeled Standards

Riociguat-13C-d3 is intended for use as an internal standard for the quantification of riociguat (Item No. 9000554) by GC- or LC-MS. Riociguat is a stimulator of soluble guanylate cyclase (sGC).{36864,26751} It stimulates recombinant sGC in a concentr...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-13C-d3-carbamic acid, methyl ester

Correlated keywords:

1304478-72-5 BAY 63-2521 BAY63-2521 BAY632521 deuterated deuterium GCMS LCMS PD-1 2 3 4 5 6 7 8 9 11 U46619

Product Overview:
Riociguat-13C-d3 is intended for use as an internal standard for the quantification of riociguat (Item No. 9000554) by GC- or LC-MS. Riociguat is a stimulator of soluble guanylate cyclase (sGC).{36864,26751} It stimulates recombinant sGC in a concentration-dependent manner in vitro by up to 73-fold when used at a concentration of 100 μM and by up to 112-fold when used in combination with the nitric oxide (NO) donor DEA NONOate (Item No. 82100).{36864} It has no effect on phosphodiesterases PDE1-9 and PDE11 when used at concentrations up to 3 μM. Riociguat (1 and 10 mg/kg) reduces pulmonary and systemic arterial pressure in a rabbit model of acute pulmonary arterial hypertension (PAH) induced by U-46619 (Item No. 16450). It also inhibits increases in right ventricular systolic pressure, right heart hypertrophy, and pulmonary artery muscularization in hypoxia-induced mouse and monocrotaline-injected rat models of chronic PAH when administered at a dose of 10 mg/kg. Formulations containing riociguat have been used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH.

Size	500 µg
Shipping	dry ice
Molecular Formula	C₁₉[¹³C]H₁₆D₃FN₈O₂
SMILES	FC1=CC=CC=C1CN2C(N=CC=C3)=C3C(C4=NC(N)=C(N([13C]([2H])([2H])[2H])C(OC)=O)C(N)=N4)=N2
Molecular Weight	426,4
Formulation	A solid
Purity	≥99% deuterated forms (d1-d3)
Custom Code	3822.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.